Non-invasive platform delivers catheter-free urodynamic testing, converting bladder activity into clinically meaningful diagnostic data

非侵入性平台提供无导管的尿动力学测试，将膀胱活动转化为具有临床意义的诊断数据。

JERSEY CITY, N.J. and OR YEHUDA, Israel

新泽西州泽西市和以色列奥尔耶胡达

,

，

May 14, 2026

2026年5月14日

/PRNewswire/ -- Urologic Health Inc., a medical device company pioneering non-invasive urodynamics, today announced the successful closing of an $11 million seed financing round led by an undisclosed strategic investor, with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors.

/PRNewswire/ -- 泌尿健康公司（Urologic Health Inc.），一家致力于非侵入性尿动力学的医疗器械公司，今天宣布成功完成了由一位未披露的战略投资者领投的1100万美元种子轮融资，Edge Medical Ventures、SHD Partners、Longevity Venture Partners以及其它专注于医疗保健的投资者也参与了本轮融资。

The funding will support the company's clinical validation, FDA 510(k) regulatory pathway, and initial U.S. commercialization efforts..

这笔资金将支持该公司的临床验证、FDA 510(k) 监管途径以及美国市场的初期商业化努力。

Bladder dysfunction conditions, including overactive bladder, urinary retention, incontinence, and benign prostatic hyperplasia (BPH), affect hundreds of millions of people worldwide, often requiring ongoing clinical assessment. Current diagnostic tools remain constrained by their high invasiveness and discomfort, which often leads patients to defer or avoid necessary assessments.

膀胱功能障碍疾病，包括膀胱过度活动症、尿潴留、尿失禁和良性前列腺增生（BPH），影响着全球数亿人，通常需要持续的临床评估。目前的诊断工具仍然受限于其高侵入性和不适感，这常常导致患者推迟或避免必要的检查。

Urologic Health's non-invasive niu.

泌尿健康非侵入性牛。

™

™

System is the first and only system designed to close that gap by delivering comprehensive bladder function data without any catheterization, supporting routine, repeatable assessment and longitudinal monitoring of bladder function.

系统是首个也是唯一一个旨在通过提供全面的膀胱功能数据来弥补这一差距的系统，无需任何导尿操作，支持常规、可重复的评估以及膀胱功能的纵向监测。

'Invasive urodynamics remains one of the most significant barriers in modern urological care,' said Adam Yaacov, Co-founder and CEO of Urologic Health. 'While treatment options have evolved considerably, the invasive diagnostic process continues to present challenges for patients. Urologic aims to make bladder function assessment easier for clinicians to perform, painless for patients to undergo, and more informative for longitudinal decision-making.'.

“侵入性尿动力学检查仍然是现代泌尿外科护理中最重要的障碍之一，”泌尿健康公司联合创始人兼首席执行官亚当·亚阿科夫表示。“尽管治疗选择已经有了显著的发展，但侵入性的诊断过程仍然给患者带来挑战。泌尿健康公司的目标是让临床医生更容易进行膀胱功能评估，让患者无痛接受检查，并为长期决策提供更多信息。”

Urologic Health has completed early feasibility studies demonstrating that the niu System can capture clinically meaningful bladder activity non-invasively. The company plans to use the new financing to advance clinical validation, continue product and manufacturing development, and establish its headquarters in Jersey City, NJ, in preparation for initial U.S.

泌尿健康公司已完成早期可行性研究，证明 niu 系统能够以非侵入方式捕捉到具有临床意义的膀胱活动。该公司计划利用新的融资来推进临床验证、继续产品和制造开发，并在新泽西州泽西市设立总部，为进入美国市场做准备。

market entry..

市场进入。。

'Urologic Health was established through our unique venture creation model, which works together with strategic industry partners to identify needs and address them by bringing together talented entrepreneurs to build high-potential medical device companies,' said Shai Policker, Managing Partner of Edge Medical Ventures and chairman of Urologic's board.

“泌尿健康是通过我们独特的风险创建模式建立的，该模式与战略行业合作伙伴共同识别需求，并通过汇集才华横溢的企业家来建立高潜力的医疗器械公司以解决这些问题，”Edge Medical Ventures管理合伙人兼Urologic董事会主席Shai Policker表示。

'By combining exceptional engineering talent in Israel with Edge's operational support, we are able to help companies like Urologic Health move faster through clinical validation, regulatory execution, and early market entry in the United States.'.

“通过将以色列卓越的工程人才与Edge的运营支持相结合，我们能够帮助像Urologic Health这样的公司更快地通过临床验证、监管执行以及进入美国的早期市场。”

About Urologic Health

泌尿健康

Urologic Health is a medical device company developing non-invasive diagnostic technology for bladder function assessment. Its niu™ System is designed to capture bladder activity as clinically meaningful diagnostic data without catheterization, supporting more routine and repeatable urodynamic assessment.

泌尿健康是一家医疗设备公司，致力于开发用于膀胱功能评估的非侵入性诊断技术。其niu™系统旨在无需导尿的情况下捕获膀胱活动作为具有临床意义的诊断数据，支持更常规且可重复的尿动力学评估。

The company was co-founded by Adam Yaacov and Dr. Noam Omer, who bring expertise in developing innovative medical technologies that advance healthcare through AI-driven insights and data-centric clinical solutions. Urologic Health was founded and incubated at the MEDX Xelerator venture studio (now EdgeLabs) and operates as part of the Edge Medical Ventures portfolio, with operations in the United States and Israel..

该公司由亚当·雅各布和诺姆·奥默博士共同创立，他们带来了通过人工智能驱动的洞察力和以数据为中心的临床解决方案来推动医疗保健的创新医疗技术开发的专业知识。泌尿健康公司成立于MEDX Xelerator风险工作室（现为EdgeLabs）并在此孵化，作为Edge Medical Ventures投资组合的一部分运营，在美国和以色列设有业务。

The niu

牛

™

™

System is not yet approved for sale in the United States and is currently limited to investigational use.

该系统尚未获准在美国销售，目前仅限于研究用途。

For more information, visit

欲了解更多信息，请访问

https://www.urologic.health/

https://www.urologic.health/

.

。

Media Contact

媒体联系人

Aviva Sapir

阿维娃·萨皮尔

Number 10 Strategies

第10号策略

[email protected]

电子邮件地址

SOURCE Urologic Health Inc.

来源：泌尿健康公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示